Actively Recruiting
Myocardial Dysfunction Evaluation in Lower Extremity Arterial Disease Patients With Deformation Analysis
Led by Tartu University Hospital · Updated on 2025-12-16
162
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.
CONDITIONS
Official Title
Myocardial Dysfunction Evaluation in Lower Extremity Arterial Disease Patients With Deformation Analysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For LEAD group: Fontaine I-IV class symptoms
- For LEAD group: Confirmed diagnosis of lower extremity arterial disease
- For control group: Age between 35 and 85 years
- For control group: Has at least one of the following: hypertension, diabetes, coronary artery disease, or smokes
You will not qualify if you...
- Age younger than 35 or older than 85 years
- Body mass index (BMI) 40 kg/m�b2 or higher
- Known history of heart failure
- Any acute or chronic autoimmune or rheumatic disease
- History of cardiac structural diseases such as inflammatory, infiltrative diseases, or nonischemic cardiomyopathies
- Acute coronary syndrome within the last 3 months
- Moderate to severe cardiac valvular disease
- History of operative or invasive treatment for cardiac valvular disease
- Presence of cardiac implantable electronic device (CIED)
- Transitory ischemic attack or stroke within the last 3 months
- Severe chronic obstructive pulmonary disease (COPD) classified as GOLD C or D
- Moderate to severe asthma according to GINA 2022 criteria
- Untreated hypertension with blood pressure 180/110 mmHg during recruitment
- Chronic severe kidney dysfunction with eGFR less than 30 ml/min/1.73 m�b2
- History of malignant tumor with radiation treatment to the chest, oncologic or biologic treatment
- Chronic hematologic disease except anemia
- Severe liver dysfunction
- Malignant tumor with less than 5 years of remission
- Acute or chronic infectious disease
- Anemia with hemoglobin less than 80 g/L
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tartu University Hospital
Tartu, Estonia
Actively Recruiting
Research Team
J
Jaak Kals, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here